AmanMG, SinghNN, StewartAW, et al.The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. Am J Ment Defic.1985;89(5):485–491.
2.
BolognaniF, Del Valle RubidoM, SquassanteL, et al.A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Sci Transl Med.2019;11(491):eaat7838; doi: 10.1126/scitranslmed.aat7838
3.
BölteS. Social cognition in autism and ADHD. Neurosci Biobehav Rev.2025;169:106022; doi: 10.1016/j.neubiorev.2025.106022
4.
de la Higuera-GonzalezP, Galvez-MerlinA, Rodriguez-ToscanoE, et al.Assessment of theory of mind in psychopathology: A scoping review. Eur Psychiatry2023;66(S1):e45–eS1002; doi: 10.1192/j.eurpsy.2023.2127
5.
HappeFGE. An advanced test of theory of mind: Understanding of story characters’ thoughts and feelings by able autistic, mentally handicapped, and normal children and adults. J Autism Dev Disord.1994;24(2):129–154; doi: 10.1007/BF02172093
6.
KaatAJ, LecavalierL, AmanMG. Validity of the aberrant behavior checklist in children with autism spectrum disorder. J Autism Dev Disord.2014;44(5):1103–1116; doi: 10.1007/s10803-013-1970-0
7.
MaedaK, SuginoH, AkazawaH, et al.Brexpiprazole I: In vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther.2014;350(3):589–604; doi: 10.1124/jpet.114.213793
8.
McCrackenJT, McGoughJ, ShahB, et al.; Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med.2002;347(5):314–321; doi: 10.1056/NEJMoa013171
9.
OwenR, SikichL, MarcusRN, et al.Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics.2009;124(6):1533–1540; doi: 10.1542/peds.2008-3782
10.
PernerJ, WimmerH. “John thinks that Mary thinks that…”: Attribution of second-order beliefs by 5- to 10-year-old children. J Exp Child Psychol1985;39(3):437–471; doi: 10.1016/0022-0965(85)90051-7
11.
SikichL, KolevzonA, KingBH, et al.Intranasal oxytocin in children and adolescents with autism spectrum disorder. N Engl J Med.2021;385(16):1462–1473; doi: 10.1056/NEJMoa2103583
12.
van den MunkhofHE, ArntJ, CeladaP, et al.The antipsychotic drug brexpiprazole reverses phencyclidine-induced disruptions of thalamocortical networks. Eur Neuropsychopharmacol.2017;27(12):1248–1257; doi: 10.1016/j.euroneuro.2017.10.034
13.
WardC, ChildressA, MartinkoK, et al.Safety and efficacy of brexpiprazole in the treatment of irritability associated with autism spectrum disorder: An 8-week, phase 3, randomized, double-blind, placebo-controlled trial and 26-week open-label extension in children and adolescents. J Child Adolesc Psychopharmacol.2025;35(4):194–201; doi: 10.1089/cap.2024.0118
14.
YoshimiN, FujitaY, OhgiY, et al.Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: A role for serotonin 5-HT1A receptors. Pharmacol Biochem Behav.2014;124:245–249; doi: 10.1016/j.pbb.2014.06.008
